// App-Quantinova.ai

Mo1092 : Cost-Utility Analysis Shows Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Researchers

Presenter

  • Thanh Nguyen

Principal Investigators

  • Victoria Ung

  • Richard N. Fedorak

  • Christopher Ma

  • Karen Wong

  • Karen Kroeker

  • Thomas Lee

  • Haili Wang

  • Arto Ohinmaa

  • Phil Jacobs

  • Brendan P. Halloran

Medical Centers

  • Institute of Health Economics, Edmonton, Alberta, Canada

  • University of Alberta Hospital, Edmonton, Alberta, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved